Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) EBITDA
Charles River Laboratories International, Inc.'s EBITDA for fiscal 2025 was $593.5M, down 26.2% from $804.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $553.0M. Over the past ten years it has ranged from $301.3M (fiscal 2015) to $954.8M (fiscal 2022); the current reading is higher than 55% of that period. EBITDA has fallen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 15th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $593.5M | (26.19%) |
| FY2024 | $804.1M | (13.67%) |
| FY2023 | $931.4M | (2.46%) |
| FY2022 | $954.8M | 11.63% |
| FY2021 | $855.4M | 28.12% |
| FY2020 | $667.7M | 21.56% |
| FY2019 | $549.2M | 11.37% |
| FY2018 | $493.2M | 17.58% |
| FY2017 | $419.4M | 15.16% |
| FY2016 | $364.2M | 20.87% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $187.2M | 0.07% |
| Mar 2026 | $187.0M | — |
| Dec 2025 | −$40.2M | — |
| Sep 2025 | $219.0M | (0.31%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| RVTY Revvity Inc. compare | $775.8M |
| ICLR ICON PLC compare | $666.9M |
| QGEN QIAGEN N.V. compare | $651.0M |
| MEDP Medpace Holdings, Inc. compare | $611.2M |
| CRL Charles River Laboratories International, Inc. | $553.0M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CRL
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement